Haematological Oncology Mutations Flashcards
(40 cards)
What mutations are common in the Myeloproliferative Neoplasms (PV, ET, MF)?
- JAK2 V617F - can be tested using ddPCR
- BCR-ABL - can be tested using RT-PCR / RQ-PCR)
- KIT D816V - can be tested using ddPCR
What is the defining mutation in CML?
- t(9;22)(q34;q11) - Ph - BCR-ABL1 - can be tested using G-banding, FISH, RT-PCR, RQ-PCR
What mutations may be detected in CML other than the Ph translocation?
Variants such as t(8;9;22)
AKD testing for mutations (sequencing)
Major route mutations in Ph+ cells include:
- Trisomy 8, Trisomy 19
- +der(22) or ider(22) - gain of BCR-ABL
- i(17)(q10)
What are the major route mutations in Ph+ cells in CML?
The chromosome changes occurring in excess of the Ph in CML are clearly nonrandom and two pathways of cytogenetic evolution may be distinguished.
Major route mutations in Ph+ cells include:
- Trisomy 8, Trisomy 19
- +der(22) or ider(22) - gain of BCR-ABL
- i(17)(q10)
What mutations are associated with a favourable risk in AML?
Good prognosis/Favourable risk:
- t(8;21)(q22;q22.1); RUNX1-RUNXT1
- Inv(16)(p13.1q22) or t(16;16); CBFB-MYH11
- NPM1 mutations without FLT3-ITD
- Biallelic CEBPA mutations
What mutations are associated with a adverse risk in AML?
Poor prognosis/Adverse risk
- t(6;9)(p23;q34.1); DEK-NUP214
- t(v;11q23.3); KMT2A rearrangement (except t(9;11))
- t(9;22)(q34;q11); BCR-ABL1
- inv(3)(q21q26) or t(3;3); GATA2, MECOM (EVI1)
- Complex karyotype, monosomal karyotype
- -5, del(5q), -7, -17, abnormal 17p
- WT NPM1 and FLT3-ITD
In AML what genes are associated with t(8;21)(q22;q22.1)?
- t(8;21)(q22;q22.1) = RUNX1-RUNXT1
In AML what genes are associated with Inv(16)(p13.1q22) or t(16;16) ?
Inv(16)(p13.1q22) or t(16;16) = CBFB-MYH11
In AML what risk is t(8;21)(q22;q22.1) associated with?
Favourable Risk - t(8;21)(q22;q22.1); RUNX1-RUNXT1
In AML what risk is Inv(16)(p13.1q22) or t(16;16) associated with?
Favourable Risk - Inv(16)(p13.1q22) or t(16;16); CBFB-MYH11
In AML what risk are NPM1 mutations without FLT3-ITD associated with?
Favourable Risk - NPM1 mutations without FLT3-ITD
In AML what risk are Biallelic CEBPA mutations associated with?
Favourable Risk - Biallelic CEBPA mutations
In AML what risk is t(6;9)(p23;q34.1); DEK-NUP214 associated with?
Poor Prognosis - t(6;9)(p23;q34.1); DEK-NUP214
In AML what risk is t(v;11q23.3); KMT2A rearrangement (except t(9;11)) associated with?
Poor Prognosis - t(v;11q23.3); KMT2A rearrangement (except t(9;11))
In AML what risk is t(9;22)(q34;q11); BCR-ABL1 associated with?
Poor Prognosis - t(9;22)(q34;q11); BCR-ABL1
In AML what risk is inv(3)(q21q26) or t(3;3); GATA2, MECOM (EVI1) associated with?
Poor Prognosis - inv(3)(q21q26) or t(3;3); GATA2, MECOM (EVI1)
In AML what risk is a complex karyotype or a monosomal karyotype associated with?
Poor Prognosis - Complex karyotype, monosomal karyotype
In AML what risk is -5 associated with?
-5 = Poor Prognosis -
In AML what risk is WT NPM1 and FLT3-ITD associated with?
Poor Prognosis - WT NPM1 and FLT3-ITD
In AML what prognosis is del(5q) associated with?
del(5q) = poor prognosis
In AML what prognosis is -7 associated with?
-7 = poor prognosis
In AML what prognosis is -17 associated with?
-17 = poor prognosis
In AML what prognosis is abnormal 17p associated with?
abnormal 17p = poor prognosis
What mutations are classified as high risk in AML?
High risk in ALL:
- iAMP21 (B)
- Low hypodiploidy (B)/near haploidy (C)
- t(17;19)/TCF3-HLF (C)
- t(9;22)/BCR-ABL1 (B)
- MLL (KMT2A) translocations (B)
- Complex karyotype (A)